Inhibikase Therapeutics (IKT) Cash from Investing Activities (2022 - 2026)

Inhibikase Therapeutics (IKT) has 5 years of Cash from Investing Activities data on file, last reported at -$80.5 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$80.5 million, down 482.27% year-over-year; the trailing twelve-month figure through Mar 2026 was -$99.5 million (down 687.19% YoY), and the FY2025 annual result was $2.1 million, up 105.55% from the prior year.
• Cash from Investing Activities slipped to -$80.5 million in Q1 2026 per IKT's latest filing, from -$98847.0 in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $21.1 million in Q1 2025 and troughed at -$80.5 million in Q1 2026.
• A 5-year average of -$7.5 million and a median of -$70968.0 in 2022 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities jumped 6017.7% in 2023, then slumped 1732.19% in 2024.
• A 5-year view of Cash from Investing Activities shows it stood at $5.0 million in 2022, then tumbled by 142.63% to -$2.1 million in 2023, then tumbled by 1732.19% to -$38.8 million in 2024, then jumped by 99.74% to -$98847.0 in 2025, then sank by 81323.4% to -$80.5 million in 2026.
• Business Quant data shows IKT's Cash from Investing Activities at -$80.5 million in Q1 2026, -$98847.0 in Q4 2025, and -$28.7 million in Q3 2025.